This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Lemaitre Vascular (LMAT) and Gilead Sciences (GILD)

Tipranks - Tipranks - Thu Jun 4, 7:56AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ardent Health Partners, Inc. (ARDT), Lemaitre Vascular (LMAT) and Gilead Sciences (GILD) with bullish sentiments.

Claim 55% Off TipRanks

Ardent Health Partners, Inc. (ARDT)

In a report released today, Jailendra Singh from Truist Financial reiterated a Buy rating on Ardent Health Partners, Inc.. The company’s shares closed last Tuesday at $9.27.

According to TipRanks.com, Singh has 0 stars on 0-5 stars ranking scale with an average return of -11.9% and a 36.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Privia Health Group. ;'>

Ardent Health Partners, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $12.54, implying a 36.9% upside from current levels. In a report released today, Guggenheim also maintained a Buy rating on the stock with a $13.00 price target.

See the top stocks recommended by analysts >>

Lemaitre Vascular (LMAT)

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Lemaitre Vascular, with a price target of $120.00. The company’s shares closed last Tuesday at $91.62.

According to TipRanks.com, Petusky is a 1-star analyst with an average return of -0.9% and a 41.1% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Lifecore Biomedical, and US Physical Therapy. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lemaitre Vascular with a $123.00 average price target, which is a 35.9% upside from current levels. In a report issued on May 29, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $113.00 price target.

Gilead Sciences (GILD)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Gilead Sciences. The company’s shares closed last Tuesday at $127.57.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 15.0% and a 45.0% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $160.11 average price target, implying a 24.1% upside from current levels. In a report issued on May 20, Maxim Group also upgraded the stock to Buy with a $165.00 price target.

Read More on ARDT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).